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1. Introduction 
The onset of asthma may be related to Th2 cytokine dominance at the time when food 
allergies occur several months after birth. This study investigated the effectiveness of early 
intervention with a Th2 cytokine inhibitor (suplatast tosilate) for prevention of asthma in 
infants with food allergies and atopic dermatitis. Suplatast tosilate dry syrup (6 mg/kg 
daily) or a histamine H1-blocker (ketotifen fumarate dry syrup: 0.06 mg/kg daily) was 
administered randomly to 53 infants with atopic dermatitis caused by food allergies. The 
primary endpoints were the incidence of asthma and the time to the onset of wheezing. The 
peripheral blood Th1/Th2 ratio, total IgE level, and eosinophil count were measured before 
and after treatment. After 24 months of treatment, the prevalence of asthma was 
significantly lower in the suplatast group (20.8%) than in the ketotifen group (65.6%, p < 
0.01). Additionally, the time from the start of treatment to the initial episode of wheezing for 
infants who developed asthma was significantly longer in the suplatast group than the 
ketotifen group (p < 0.01). Furthermore, the eosinophil count was significantly decreased by 
suplatast treatment (p < 0.05), and there was a significant difference between the suplatast 
and ketotifen groups with respect to both the eosinophil count (p < 0.01) and the Th1/Th2 
ratio (p < 0.05). The results of the present pilot study suggest that suplatast tosilate is useful 
for the primary prevention of wheezing and asthma in children. 
2. Atopic dermatitis is associated with asthma 
Asthma frequently develops by the age of 3 yr (1) and recent research has demonstrated that 
its onset is tending to occur at a younger age (2). Various hypotheses have been suggested 
with respect to the etiology of asthma. According to the Tucson cohort study performed in 
the United States, there is a low probability of atopic asthma developing in infants with 
recurrent wheezing up to the age of 3 yr, and they are considered to be a separate 
population from the infants in whom recurrent wheezing persists until later childhood (3). 
In the former group, viral infection is the direct cause of wheezing, while the latter group 
have an atopic constitution and their asthma may persist during the school years and even 
into adulthood. Thus, this latter group may be a population for which early intervention is 
important. It is known that chronic asthma is more likely to develop in patients who are 
positive in tests for food or house dust allergens (4, 5). The rate of progression to adult 
asthma is also high among individuals who test positive for food allergens, such as those in 
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eggs or milk, during early infancy (6), while another study has shown that the strongest risk 
factor for life- threatening asthma is the presence of food allergy (7). Atopic dermatitis was 
reported to be associated with asthma that has a later onset (8), while inhibition of the 
occurrence of asthma has been reported in dermatitis patients treated with H1-blocker 
therapy (9, 10). 
2.1 Th2 cytokine inhibitor: Suplatast tosilate 
We have tested the preventive effect of treatment with a Th2 inhibitor, suplatast tosilate. In 
previous in vitro and in vivo studies, suplatast tosilate has been shown to inhibit the 
production of IgE antibodies, reduce tissue eosinophil infiltration, and block the production 
of IL-4 and IL-5 (11–13). More recently, it was shown to prevent goblet cell hyperplasia by 
blocking IL-13 production (14). According to a study performed in a mouse model of food 
allergy, suplatast tosilate decreases IL-4 and IL-6 production in the small intestine, and also 
ameliorates small bowel necrosis (15). In adults with asthma, suplatast tosilate shows 
comparable anti-inflammatory activity to inhaled steroids (16), as well as improving lung 
function, asthma symptoms, and airway hyperresponsiveness (16, 17). In patients receiving 
high-dose inhaled steroids, addition of suplatast tosilate allows the steroid dose to be 
reduced (18). Furthermore, evaluation by bronchial biopsy has shown that this drug 
decreases the number of eosinophils and EG2-positive cells in the airway mucosa, as well as 
inhibiting goblet cell hyperplasia (17, 19). Infants with a family history of atopy and infants 
in whom atopic disease occurs soon after birth have been reported to show a shift of the 
Th1-Th2 cytokine balance towards Th2 dominance (20, 21). Accordingly, the Th1-Th2 
balance during the early postnatal period is believed to be a key factor in determining 
whether or not allergy develops. 
2.2 Aim and method of this study 
The present study was designed to investigate early intervention in atopic dermatitis 
patients with food allergies, a population considered to be at high risk for the development 
of asthma. Suplatast tosilate was chosen for early intervention therapy in the present study 
based on the hypothesis that selective inhibition of Th2 cytokines would improve the Th1-
Th2 balance in the high-risk group for asthma (children with Th2 cytokine dominance). 
Comparison was made with a histamine H1-blocker, ketotifen fumarate, as the control drug. 
2.2.1 Subject 
We studied 60 consecutive infants who presented to our department with symptoms of 
atopic dermatitis caused by food allergies that had persisted for at least 2 month. All of the 
infants had a family history (at least one parent) of atopic disease, such as bronchial asthma, 
allergic rhinitis, or atopic dermatitis. The diagnosis of atopic dermatitis was based on the 
criteria of the Japanese Dermatological Association (22), and all of the infants had 
predisposing factors for atopic disease (a family history of atopy, a history of allergic 
disease, or a predisposition to IgE production). They primarily developed pruritic eczema 
that showed repeated episodes of exacerbation and remission. Only infants with chronic 
dermatitis that had persisted for 2 months or more were diagnosed as having atopic 
dermatitis. Food allergies were diagnosed from the history using the following criteria: (i) a 
history of skin disease influenced by food, and (ii) a raised serum level of specific IgE for 
cow’s milk or egg white (CAP RAST class ‡2). Children were excluded who had a history 
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suggesting the prior existence of asthma, such as wheeze and chronic cough unrelated to 
respiratory tract infection. Infants who had used oral sodium cromoglycate or other 
antiallergy drugs within the previous 4 wk (agents that could potentially affect the outcome 
of this study) were also excluded, but those using topical steroids rated as medium strength 
or weak to control atopic dermatitis were permitted to enter the study. 
2.2.2 Study design 
Thirty children were randomly assigned to oral treatment with suplatast tosilate dry syrup 
(IPD dry syrup 5%, Taiho Pharmaceutical Co. Ltd, Tokyo Japan) at a dose of 3 mg/kg twice 
daily (the total daily dose was 6 mg/kg) and 30 were assigned to receive ketotifen fumarate 
dry syrup at dose of 0.03 mg/kg twice daily (the total daily dose was 0.06 mg/kg). Both 
these drugs were administered for at least 2 yr, and could be continued for up to 4 yr at the 
request of the parents. After the start of the study, subjects were reviewed at the outpatient 
department once monthly until completion of the study. Blood was collected at the start and 
after 6 months of treatment for measurement of the total IgE level; the specific IgE levels for 
egg white, cow’s milk, Der P, and house dust mite; the eosinophil count; and the Th1/Th2 
ratio. The primary endpoints of this study were the incidence of asthma and the time to the 
initial episode of wheezing among the patients in whom asthma occurred. Wheezing was 
confirmed by the authors via auscultation, and the date of the initial of wheezing, as well as 
subsequent episodes of wheezing and persistent cough excluding those caused by infection, 
was recorded in each infant. Asthma was defined as the occurrence of three or more 
episodes of wheezing associated with expiratory dyspnea, and the day of onset of asthma 
was defined as the day when the initial episode of wheezing occurred in each patient with 
asthma. The secondary endpoints of this study were the percentage of patients admitted to 
hospital because of asthma and changes of the peripheral blood eosinophil count, IgE level, 
and Th1/Th2 ratio. For the treatment of atopic dermatitis and food allergies, the use of 
concomitant drugs other than medium-strength to weak topical steroids was not allowed 
during the study period. After the onset of asthma, antiasthma medications, mainly anti-
inflammatory drugs, could be prescribed. 
2.2.3 Measurement of the Th1/Th2 ratio 
The Th1/Th2 ratio was measured by flow cytometry using a FACScan (23). In brief, CD4-
positive cells (helper T cells) were isolated. Then Th2 cytokine-positive cells were detected 
and counted after staining with an anti-IL-4 antibody, while Th1 cytokine – positive cells 
were identified with an anti-IFN-c antibody, after which the Th1/Th2 ratio was 
calculated. 
2.2.4 Measurement of serum total IgE and specific IgE 
Serum total IgE was measured using a fluoroenzyme immunoassay (FEIA) (CAP RIST FEIA, 
Pharmacia, Uppsala, Sweden). The levels of specific IgE for house dust mite, Der P, egg 
white, and cow’s milk were measured using FEIA (CAP RAST FEIA, Pharmacia). 
2.2.5 Ethics 
This study was approved by the Regional Ethics Committee for Human Research at Dokkyo 
University School of Medicine Hospital. The parents of all patients participating in this 
study gave oral and written informed consent. 
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2.2.6 Statistical analysis 
The initial wheezing episodes were plotted by the Kaplan–Meier method, and p-values were 
calculated with the log-rank test. Pearson’s chisquared test was used to analyze the 
incidence of asthma. The Th1/Th2 ratio, total IgE level, and eosinophil count were 
compared between before and after treatment using the paired t-test. It was employed to 
determine the significance of differences between the two treatments. Results were 
expressed as the mean ± s.e., and p-values of <0.05 were considered to indicate statistical 
significance. 
2.3 Result of this study 
A total of seven infants were excluded from the study: three infants were excluded because 
their parents did not allow their children to receive suplatast tosilate, while four infants 
were excluded because they stopped attending the hospital for various reasons. As a result, 
there were 29 infants in the ketotifen group and 24 in the suplatast group. The clinical 
profile of each group is shown in the Table 1.  
 
 
Ketotifen group
(n = 29) 
Suplatast group
(n = 24) 
p-value 
Sex 
Males 22, 
female 7 
Males 18, 
female 6 
0.942 
Age (days) 370.9±78.7 365.5±80.5 0.728 
Age at onset (days) 145.1±34.5 134.4±19.7 0.633 
No. of days from onset to drug 
treatment (days) 
225.8±69.4 231.0±77.7 0.837 
Total IgE (IU/ml) 509.2±209.6 745.7±207.0 0.24 
Egg IgE (Class) 2.50±0.26 3.36±0.31 0.0188 
Milk IgE (Class) 2.09±1.87 3.69±0.37 0.0273 
House dust mite IgE (Class) 1.25±0.49 1.56±0.59 0.814 
Der P IgE (Class) 1.31±0.48 1.73±0.64 0.752 
Table 1. Clinical profile 
There were no significant differences between the two groups with respect to the sex ratio, 
age, time of onset of atopic dermatitis, number of days from onset to drug treatment. The 
mean age at the start of treatment was 365.5 ± 80.5 days in the 24 infants who received 
suplatast tosilate and 370.9 ± 78.7 days in the 29 who received ketotifen fumarate. 
There were no differences between the suplatast group and the ketotifen group with respect 
to the total IgE level or the levels of specific IgE for house dust mite or Der P before 
treatment. However, the specific IgE levels for egg white and milk were significantly higher 
in the suplatast group. 
The incidence of asthma was significantly lower in the suplatast group than the ketotifen 
group, with asthma occurring in five out of 24 patients from the former group (20.8%) vs. 19 
out of 29 patients from the latter group (65.6%, p < 0.01). Additionally, the time from the 
start of drug treatment to the onset of wheezing among patients in whom asthma occurred 
was significantly longer in the suplatast group than the ketotifen group (p < 0.01, Fig. 1). 
The percentage of infants who were admitted to hospital for the treatment of asthma was 
significantly lower (p < 0.05) in the suplatast group (one out of 24 patients, or 4.2%) than in 
the ketotifen group (seven out of 29 patients, or 24.1%). 
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Fig. 1. Onset of wheezing during treatment with a Th2 cytokine inhibitor (suplatast tosilate) 
or a histamine H1-blocker (ketotifen fumarate). 
The eosinophil count decreased significantly from 1.212 ± 174 to 679 ± 111/lL (p < 0.05) after 
219 ± 42 days of suplatast treatment (n = 21), while no significant change was observed after 
280 ± 44 days of ketotifen treatment (n = 19). The change after treatment was significantly 
larger (p < 0.01) in the suplatast group (-532.4 ± 120.0) compared with the ketotifen group (-2.1 
± 126.0) (Fig. 2). Although there was no significant change of the Th1/Th2 ratio after treatment 
in either the suplatast group (from 4.88 ± 1.07 to 6.76 ± 1.58%, n = 16) or the ketotifen group 
(from 10.00 ± 8.52 to 6.44 ± 1.88% n = 10), there was a significant difference of the ratio between 
the two groups (p < 0.05) (Fig. 3). However, there was no significant difference between the 
groups with respect to changes of the total IgE level (data not shown). 
 
 
Fig. 2. Eosinophil count before and after treatment with suplatast tosilate (-532.4 ± 120.0) or 
ketotifen fumarate (-2.1 ± 126.0); *p < 0.01 by the t-test. 
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Fig. 3. Th1/Th2 ratio before and after treatment with suplatast tosilate (1.88 ± 1.57) or 
ketotifen fumarate (-3.56 ± 1.99); *p < 0.05 by the t-test. 
No adverse events and no laboratory abnormalities were observed in the suplatast group. 
Two episodes of sedation occurred in the ketotifen group, but these were transient and did 
not result in the discontinuation of therapy. 
2.4 Effectiveness of early intervention with a Th2 cytokine inhibitor 
Children with a family history of allergic disease are likely to have a predisposition to atopy 
and the processes leading to the development of such diseases may commence in utero. 
After birth, continuous exposure to certain food antigens may sequentially trigger allergic 
reactions that manifest as food allergies, atopic dermatitis, asthma, and allergic rhinitis. Such 
reactions are involved in the progression of allergic disease (24, 25). Treatment designed to 
suppress the exacerbation of allergic airway inflammation may potentially have an 
important role in the prophylaxis and management of these diseases. 
We compared the inhibitory effect of suplatast tosilate and the H1-blocker ketotifen fumarate 
on the onset of asthma in patients with atopic dermatitis who were positive for egg-white or 
milk allergens. When ketotifen was previously tested in 121 infants with atopic dermatitis who 
were treated for a 1-yr period, it reduced the occurrence of asthma compared with placebo, 
and the subgroup of children with a high IgE level showed a significant benefit (9). After 24 
months of treatment in the present study, however, asthma developed in 65.6% of the patients 
receiving ketotifen vs. only 20.8% of those treated with suplatast. To assess the prevention of 
progression to severe asthma, we analyzed the number of patients who required hospital 
treatment for their asthma. Seven out of 29 infants from the ketotifen group and only one out 
of 24 infants from the suplatast group were admitted to hospital for the treatment of asthma, 
with the percentage being significantly lower in the suplatast group. This finding suggests the 
possibility that suplatast can prevent progression of mild asthma to severe asthma. 
To examine the systemic effects of suplatast (a Th2 cytokine inhibitor) vs. those of ketorifen (an 
antihistamine), the Th1/Th2 ratio, total IgE level, and eosinophil count were measured before 
and after treatment. As a result, the Th1/Th2 ratio was found to be significantly higher after 
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treatment in the suplatast group than in the ketotifen group, but neither drug decreased the 
serum IgE level. Based on the previous report that 3 or 6 months of treatment with suplatast 
tosilate decreased the serum levels of IgE and IL-4 in adults with perennial allergic rhinitis 
(26), we assessed the changes of parameters over a 6-month period in this study. The failure of 
suplatast tosilate to suppress IgE production may have been related to the low age of the 
subjects in the suplatast group (mean age at the start of treatment with suplatast: 365.5 days), 
because there is a gradual increase of tolerance to food allergens such as egg white and cow’s 
milk, while sensitization to inhaled allergens like Der P and house dust mite shows a rapid 
increase at this age and infants with an atopic tendency show increased IgE synthesis at this 
age (27). Accordingly, we were not able to assess the efficacy of suplatast from the total IgE 
level. The Early Treatment of the Atopic Child (ETAC) study investigated the use of cetirizine, 
an H1-blocker like ketotifen for preventing the onset of asthma and found no significant 
overall benefit compared with the placebo, although asthma was prevented in patients 
sensitized to house dust mite or grass pollen (10). Our patients had high antibody titers for 
food allergens, but their mean baseline CAP RAST scores were 2 or less for both house dust 
mite and Der P. This suggests that suplatast was more effective than H1-blockers for patients 
who were not strongly sensitized to inhaled allergens. As we did not initially plan to assess 
changes of specific IgE levels in the present study, these parameters were only measured in a 
few patients after the start of treatment. Therefore, drawing firm conclusions is impossible, but 
we plan to investigate further whether suplatast has a similar effect to that of immunotherapy, 
which prevents the development of new allergies (e.g., suppresses reactions to inhaled 
allergens) (28). In the present study, we directed our attention to the Th1/Th2 ratio. At birth, 
the production of INF-c is very low and infants are in a state where the immune response is 
Th2 dominant. If IFN-c production increases during the 6 months after birth, the immune 
response will become Th1 dominant and the production of IL-4 will be inhibited, preventing 
the acquisition of an atopic predisposition. In an environment that does not cause induction of 
IFN-c, however, its level gradually increases with maturity, but IL-4 also continues to be 
produced until an atopic predisposition is acquired (29). Our preliminary study showed that 
persons with a strong atopic predisposition, who developed food allergies followed by atopic 
dermatitis, asthma, and allergic rhinitis, actually had a higher Th1/Th2 ratio than healthy 
subjects and had a Th1-Th2 balance skewed toward Th2 dominance (unpublished 
observation). Such findings suggest that there is a tendency for Th2 dominance in infancy and 
that an increase of inflammation due to eosinophils, etc. may lead to the eventual onset of 
asthma. Suplatast has been shown to inhibit the activity of eosinophils by in vitro and in vivo 
studies, including research performed using peripheral blood, sputum, and bronchial tissue 
specimens obtained by biopsy (12–14, 16, 17). In the present study, suplatast significantly 
decreased the peripheral blood eosinophil count compared with ketotifen. There have been 
several reports of a relationship between the onset of asthma and eosinophils. For example, 
Bromchoalveolar lavage fluid (BALF) levels of Eosimophilic Catiomic Protein (ECP) are higher 
in patients with childhood asthma than in those with infantile wheeze (30), and persons who 
subsequently develop asthma have more Eosimophil Granulocyte-2 (EG2)- positive cells in the 
epithelium or lamina propria on bronchial biopsy than those who do not (31). 
It appears that inhibition of the onset of asthma may be attributable to two factors, which 
are a decrease of the eosinophil count and a shift of the Th1/Th2 ratio toward Th1 
dominance. The results of our study provide some corroboration for the hypothesis that 
inhibition of eosinophilic inflammation and improvement of the Th1/Th2 balance can 
contribute to preventing the onset of asthma. 
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The present investigation was only a pilot study, but it is still clinically significant that more 
than half of our patients with atopic dermatitis and food allergies developed asthma before 
age three during treatment with ketotifen, while only 20% of the suplatast group did so. 
Among the criteria in the asthma predictive index (API) (32), which is based on the Tucson 
Children’s Respiratory Study, as well as the major and minor criteria in the modified asthma 
predictive index (mAPI) (33) based on the PEAK trial, a parental history of asthma, 
physician-diagnosed atopic dermatitis, and allergic sensitization to milk, egg, or peanuts 
correspond to the criteria used in the present study. These other studies have suggested that 
early intervention with suplatast can prevent progression to chronic asthma if patients 
meeting the criteria that suggest an increased likelihood of progression to chronic asthma in 
the future are treated before they develop wheezing. Both the API and the mAPI include the 
criterion of an eosinophil count ‡4%. Most of the patients in the present study met this 
criterion and showed a significant decrease of eosinophils after treatment with suplatast. 
Therefore, early intervention with suplatast may prevent progression to chronic asthma 
even in patients with a high eosinophil count, who have an increased risk of developing 
chronic asthma. The finding that a lower percentage of patients in the suplatast group 
needed hospital admission for asthma also serves as evidence that this drug may prevent 
progression to chronic asthma. 
3. Conclusion 
There have only been a few reports about early intervention for patients with a high risk of 
developing asthma. Iikura et al. reported a research of early intervention (34). To evaluate 
the prophylactic effect of ketotifen against the onset of asthma they selected 121 infants with 
atopic dermatitis. A placebo syrup group and an active syrup group were followed for 1 
year, with bimonthly evaluations. During the 1 year study, asthma was observed in eight 
children of the ketotifen group (13.1%) and in 25 children of the placebo group (41.6%) (P 
less than .001). As a result, they concluded that Ketotifen is effective for early intervention in 
children with atopic dermatitis. 
Suplatast tosilate is an oral agent that has been available in Japan for 12 yr since 1995. It is 
highly safe, and there have been no reports of serious adverse reactions to this drug (35). 
The manufacturer of Suplatast, (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) summarized 
the adverse events that were detected among 154 children under 3 yr old in a study of actual 
use. According to this report, adverse reactions were only noted in two patients. This shows 
that Suplatast is also safe for patients under 3 yr old and thus is thus suitable for long-term 
administration to high risk patients in order to prevent the onset of asthma. It is one of the 
few drugs available that act as a non-specific regulator of the immune system. Then, it 
showed that the allergic predisposition is improved in suppressing the symptom. Therefore 
it can be said that suplatast tosilate is an antiallergic fundamentally curative drug. In the 
future, we hope to collect more cases and explore whether this drug can change the natural 
history of asthma. 
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